Regardless of chronic obstructive pulmonary disease status, finerenone mitigates clinical events and symptoms in patients with HFmrEF or HFpEF.

Finerenone treatment vs placebo was associated with a reduced risk for new-onset diabetes by 24% among patients with HFmrEF or HFpEF.

Simplified method using left atrial volume and natriuretic peptides streamlines diagnosis of heart failure with preserved ...

Heart failure with preserved ejection fraction (HFpEF ... which may favorably affect the full range of abnormalities—peripheral vascular, skeletal muscle, and cardiovascular—that contribute to ...

During aging, deterioration in cardiac structure and function leads to increased susceptibility to heart failure. The need for interventions ... While some of these are systemic processes that affect ...